OncoZenge AB (FRA:8LY) ROE % Adjusted to Book Value: -2.67% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8LY OncoZenge AB FRA:8LY
26 GF Score
Price €0.61
! 2 Warning Signs
View Full Analysis

What is OncoZenge AB ROE % Adjusted to Book Value?

OncoZenge AB FRA:8LY -4.98% 26 ROE % Adjusted to Book Value is -2.67% as of Mar. 2026. GuruFocus rates FRA:8LY with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

OncoZenge AB's ROE % for the quarter that ended in Mar. 2026 was -652.22%. OncoZenge AB's PB Ratio for the quarter that ended in Mar. 2026 was 244.00. OncoZenge AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -2.67%.

OncoZenge AB ROE % Adjusted to Book Value Related Terms

OncoZenge AB ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for OncoZenge AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoZenge AB ROE % Adjusted to Book Value Chart

OncoZenge AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -4.21 -43.69 -33.98 -13.53 -18.11

OncoZenge AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 -14.70 -15.88 -45.43 -2.67

FRA:8LY vs VRTX, REGN, RVMD: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, OncoZenge AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoZenge AB ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoZenge AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where OncoZenge AB's ROE % Adjusted to Book Value falls into.


FRA:8LY
26GF Score
OncoZenge AB FRA:8LY
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoZenge AB ROE % Adjusted to Book Value Calculation

OncoZenge AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-178.22% / 9.84
=-18.11%

OncoZenge AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-652.22% / 244.00
=-2.67%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -2.67% mean?
OncoZenge AB (FRA:8LY) has a ROE % Adjusted to Book Value of -2.67% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on OncoZenge AB and its competitors.
Is OncoZenge AB's ROE % Adjusted to Book Value too high?
OncoZenge AB's current ROE % Adjusted to Book Value is -2.67%. Overall, OncoZenge AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does OncoZenge AB's ROE % Adjusted to Book Value compare to VRTX and REGN?
OncoZenge AB's ROE % Adjusted to Book Value of -2.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on OncoZenge AB and its competitors. OncoZenge AB's current ROE % Adjusted to Book Value is -2.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoZenge AB stock overvalued right now?
OncoZenge AB (FRA:8LY) has a current ROE % Adjusted to Book Value of -2.67%. The current ROE % Adjusted to Book Value is -2.67%. OncoZenge AB's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For OncoZenge AB (FRA:8LY), the current ROE % Adjusted to Book Value is -2.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoZenge AB Business Description

Other Exchanges ONCOZ:Sweden
Address Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
26GF Score

Get the complete analysis for FRA:8LY

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.61
Price